Trodello Cameron, Higgins Shauna, Ahadiat Omeed, Ragab Omar, In Gino, Hawkins Makenzie, Wysong Ashley
Departments of Dermatology.
Radiation Oncology, and.
Dermatol Surg. 2019 Feb;45(2):254-267. doi: 10.1097/DSS.0000000000001755.
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.
To evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.
Medical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.
Of the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).
As most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.
皮肤鳞状细胞癌（cSCC）是第二常见的皮肤癌形式，具有区域或远处转移的可能性。尽管与高危cSCC（一种晚期cSCC亚型）相关的特征已标准化，但对于该肿瘤的恰当管理尚无既定共识。
评估西妥昔单抗的疗效，补充现有治疗方案，并助力制定该肿瘤的标准化治疗方法。
使用当前操作术语编码搜索有关西妥昔单抗和cSCC的医疗记录。收集人口统计学数据、肿瘤特征以及治疗方案和随访时间。共检查了20例病例。
20例病例中，3例完全缓解，7例部分缓解，总缓解率为50%，联合无病生存期的中位数为6.35个月（范围1 - 46.8个月）。
由于大多数有反应的患者接受西妥昔单抗作为多模式治疗方法的一部分，西妥昔单抗与手术或放疗等联合疗法同时使用时可能最有效。有必要开展进一步的大型前瞻性研究，以确定西妥昔单抗的最佳剂量和给药频率以及联合疗法的效用。
